Therapeutics News and Research

RSS

EPO-secreting engineered vessels could reverse anemia

Patients who rely on recombinant, protein-based drugs must often endure frequent injections, often several times a week, or intravenous therapy. Researchers at Children's Hospital Boston demonstrate the possibility that blood vessels, made from genetically engineered cells, could secrete the drug on demand directly into the bloodstream.

15 Nov 2011

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it will present new data from its ALN-TTR program at the VIIIth International Symposium on Familial Amyloidotic Polyneuropathy being held in Kumamoto, Japan from November 20-22, 2011.

15 Nov 2011

InVivo Therapeutics reports net income of $3,067,000 for third quarter 2011

InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today reported financial results for the three and nine months ended September 30, 2011 and provided a business update.

15 Nov 2011

Positive long-term data from Abbott's ABSORB drug eluting BVS trial on CAD

Abbott today announced positive long-term data from the two-stage ABSORB trial, which is evaluating the ABSORB drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease.

15 Nov 2011

Researchers explore how design of chronic and acute pain trials might be improved

For chronic pain sufferers, a day can feel like a year and a year can feel like an eternity. With very few truly new therapies approved by the U.S. Food and Drug Administration for this condition since 2005, the outlook is far from bright.

15 Nov 2011

Women with inflammatory breast cancer now have a chance of treatment

Women with the deadliest and rarest form of breast cancer now have a chance of treatment where once their options were severely limited, thanks to a new discovery by George Mason University researchers.

15 Nov 2011

Stem cell bandage human clinical trial for torn meniscal cartilage

The company behind a pioneering stem cell bandage, believed to be the world's first adult and autologous (patient's own) stem cell treatment designed to heal torn meniscal cartilage, can now take the technology to human clinical trials thanks to an investment from one of the UK's most successful entrepreneurs.

14 Nov 2011

Global demand to join pioneering adult stem cell study to treat ALS

BrainStorm Cell Therapeutics Inc., an innovative developer of adult stem cell technologies and CNS therapeutics, today announced that patients from across the globe are demanding to be included in the pioneering clinical study started earlier this year at Jerusalem's Hadassah University Medical Center.

14 Nov 2011

EntreMed third quarter net loss decreases to $1.3 million

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and nine-month periods ending September 30, 2011.

14 Nov 2011

Positive results from Oncolytics REOLYSIN combination Phase 2 clinical trial for head and neck cancers

Oncolytics Biotech Inc. today announced that positive results from a Phase 2 clinical trial (REO 015) using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

14 Nov 2011

Nile Therapeutics third quarter net loss decreases to $1.1 million

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced its third quarter financial results for 2011.

14 Nov 2011

Six-month results from BIOTRONIK's PRO-Kinetic Energy stent study presented at TCT 2011

BIOTRONIK AG announced that the six-month results of the ENERGY Registry were presented last week by Prof. Raimund Erbel at the Transcatheter Cardiovascular Therapeutics (TCT 2011) conference.

14 Nov 2011

Scientists discover molecular basis for tamoxifen resistance and potential way to defeat it

In the last three decades, thousands of women with breast cancer have taken the drug tamoxifen, only to discover that the therapy doesn't work, either because their tumors do not respond to the treatment at all, or because they develop resistance to it over time. Now researchers at the University of California, San Francisco (UCSF) have discovered the molecular basis for tamoxifen resistance and found a potential way to defeat it.

14 Nov 2011

Scientists create new phenotypic cancer drug screening platform

Researchers have created a new phenotypic screening platform that better predicts success of drugs developed to prevent blood vessel tumor growth when moving out of the lab and onto actual tumors.

14 Nov 2011

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Genzyme, a Sanofi company, reports today that the Phase lll CARE-MS ll trial met both of its co-primary endpoints. Relapse rate and sustained accumulation (worsening) of disability (SAD) were significantly reduced in multiple sclerosis patients receiving alemtuzumab as compared with Rebif.

14 Nov 2011

Next-generation drugs may prevent skin lesions in BRAF mutation-positive melanoma

Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, may have the potential to prevent drug-induced skin lesions in BRAF mutation-positive patients treated for melanoma.

14 Nov 2011

ZIOPHARM announces darinaparsin preclinical data on prostate cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that results from preclinical studies of darinaparsin (Zinapar or ZIO-101), a novel organic arsenic, in prostate cancer were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

14 Nov 2011

Combination of REGN910 and aflibercept inhibits tumor angiogenesis in animal models

Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone, according to results presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011.

14 Nov 2011

Amplification of ALK gene may drive rapid breast cancer metastasis

Amplification of anaplastic lymphoma kinase, which has been reported in other cancers such as non-small cell lung cancers, may be a primary driver of the rapid metastasis that patients with inflammatory breast cancer experience.

14 Nov 2011

Researchers show how ER-positive breast cancer tumors become resistant to tamoxifen

Researchers have shown how estrogen receptor-positive breast cancer tumors become resistant to tamoxifen, the only approved hormonal therapy for premenopausal patients with this type of breast cancer.

14 Nov 2011

Therapeutics News and Research

EPO-secreting engineered vessels could reverse anemia

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

InVivo Therapeutics reports net income of $3,067,000 for third quarter 2011

Positive long-term data from Abbott's ABSORB drug eluting BVS trial on CAD

Researchers explore how design of chronic and acute pain trials might be improved

Women with inflammatory breast cancer now have a chance of treatment

Stem cell bandage human clinical trial for torn meniscal cartilage

Global demand to join pioneering adult stem cell study to treat ALS

EntreMed third quarter net loss decreases to $1.3 million

Positive results from Oncolytics REOLYSIN combination Phase 2 clinical trial for head and neck cancers

Nile Therapeutics third quarter net loss decreases to $1.1 million

Six-month results from BIOTRONIK's PRO-Kinetic Energy stent study presented at TCT 2011

Scientists discover molecular basis for tamoxifen resistance and potential way to defeat it

Scientists create new phenotypic cancer drug screening platform

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Next-generation drugs may prevent skin lesions in BRAF mutation-positive melanoma

ZIOPHARM announces darinaparsin preclinical data on prostate cancer

Combination of REGN910 and aflibercept inhibits tumor angiogenesis in animal models

Amplification of ALK gene may drive rapid breast cancer metastasis

Researchers show how ER-positive breast cancer tumors become resistant to tamoxifen

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News